Production of biologically active human interleukin-10 by Bifidobacterium bifidum BGN4.
Animals
Base Sequence
Bifidobacterium bifidum
/ genetics
Blotting, Western
Escherichia coli
/ genetics
Gene Expression Regulation, Bacterial
HT29 Cells
Humans
Interleukin-10
/ genetics
Mice
Plasmids
/ genetics
Promoter Regions, Genetic
/ genetics
RAW 264.7 Cells
Recombinant Proteins
/ metabolism
Sequence Homology, Nucleic Acid
Bifidobacterium bifidum
Bioactive
Expression vector
Human interleukin-10
Recombinant
Secretion
Journal
Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812
Informations de publication
Date de publication:
19 Jan 2021
19 Jan 2021
Historique:
received:
26
07
2020
accepted:
29
12
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Bifidobacterium spp. are representative probiotics that play an important role in the health of their hosts. Among various Bifidobacterium spp., B. bifidum BGN4 exhibits relatively high cell adhesion to colonic cells and has been reported to have various in vivo and in vitro bio functionalities (e.g., anti-allergic effect, anti-cancer effect, and modulatory effects on immune cells). Interleukin-10 (IL-10) has emerged as a major suppressor of immune response in macrophages and other antigen presenting cells and plays an essential role in the regulation and resolution of inflammation. In this study, recombinant B. bifidum BGN4 [pBESIL10] was developed to deliver human IL-10 effectively to the intestines. The vector pBESIL10 was constructed by cloning the human IL-10 gene under a gap promoter and signal peptide from Bifidobacterium spp. into the E. coli-Bifidobacterium shuttle vector pBES2. The secreted human IL-10 from B. bifidum BGN4 [pBESIL10] was analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), Western Blotting, and enzyme-linked immunosorbent assay (ELISA). More than 1,473 ± 300 ng/mL (n = 4) of human IL-10 was obtained in the cell free culture supernatant of B. bifidum BGN4 [pBESIL10]. This productivity is significantly higher than other previously reported human IL-10 level from food grade bacteria. In vitro functional evaluation of the cell free culture supernatant of B. bifidum BGN4 [pBESIL10] revealed significantly inhibited interleukin-6 (IL-6) production in lipopolysaccharide (LPS)-induced Raw 264.7 cells (n = 6, p < 0.0001) and interleukin-8 (IL-8) production in LPS-induced HT-29 cells (n = 6, p < 0.01) or TNFα-induced HT-29 cells (n = 6, p < 0.001). B. bifidum BGN4 [pBESIL10] efficiently produces and secretes significant amounts of biologically active human IL-10. The human IL-10 production level in this study is the highest of all human IL-10 production reported to date. Further research should be pursued to evaluate B. bifidum BGN4 [pBESIL10] producing IL-10 as a treatment for various inflammation-related diseases, including inflammatory bowel disease, rheumatoid arthritis, allergic asthma, and cancer immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Bifidobacterium spp. are representative probiotics that play an important role in the health of their hosts. Among various Bifidobacterium spp., B. bifidum BGN4 exhibits relatively high cell adhesion to colonic cells and has been reported to have various in vivo and in vitro bio functionalities (e.g., anti-allergic effect, anti-cancer effect, and modulatory effects on immune cells). Interleukin-10 (IL-10) has emerged as a major suppressor of immune response in macrophages and other antigen presenting cells and plays an essential role in the regulation and resolution of inflammation. In this study, recombinant B. bifidum BGN4 [pBESIL10] was developed to deliver human IL-10 effectively to the intestines.
RESULTS
RESULTS
The vector pBESIL10 was constructed by cloning the human IL-10 gene under a gap promoter and signal peptide from Bifidobacterium spp. into the E. coli-Bifidobacterium shuttle vector pBES2. The secreted human IL-10 from B. bifidum BGN4 [pBESIL10] was analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), Western Blotting, and enzyme-linked immunosorbent assay (ELISA). More than 1,473 ± 300 ng/mL (n = 4) of human IL-10 was obtained in the cell free culture supernatant of B. bifidum BGN4 [pBESIL10]. This productivity is significantly higher than other previously reported human IL-10 level from food grade bacteria. In vitro functional evaluation of the cell free culture supernatant of B. bifidum BGN4 [pBESIL10] revealed significantly inhibited interleukin-6 (IL-6) production in lipopolysaccharide (LPS)-induced Raw 264.7 cells (n = 6, p < 0.0001) and interleukin-8 (IL-8) production in LPS-induced HT-29 cells (n = 6, p < 0.01) or TNFα-induced HT-29 cells (n = 6, p < 0.001).
CONCLUSION
CONCLUSIONS
B. bifidum BGN4 [pBESIL10] efficiently produces and secretes significant amounts of biologically active human IL-10. The human IL-10 production level in this study is the highest of all human IL-10 production reported to date. Further research should be pursued to evaluate B. bifidum BGN4 [pBESIL10] producing IL-10 as a treatment for various inflammation-related diseases, including inflammatory bowel disease, rheumatoid arthritis, allergic asthma, and cancer immunotherapy.
Identifiants
pubmed: 33468130
doi: 10.1186/s12934-020-01505-y
pii: 10.1186/s12934-020-01505-y
pmc: PMC7814708
doi:
Substances chimiques
IL10 protein, human
0
Recombinant Proteins
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Subventions
Organisme : Ministry of SMEs and Startups (KR)
ID : S2848321
Organisme : Faculty Research and Creative Activity Committee, MTSU (US)
ID : 221745
Références
Eur J Pediatr. 2001 Aug;160(8):457-63
pubmed: 11548181
J Antimicrob Chemother. 2005 Jan;55(1):38-44
pubmed: 15574479
Biotechnol Lett. 2007 Aug;29(8):1249-53
pubmed: 17487549
Bioengineered. 2014;5(6):371-7
pubmed: 25482086
PLoS One. 2015 Jun 18;10(6):e0128802
pubmed: 26086721
Front Immunol. 2013 May 31;4:129
pubmed: 23755052
Curr Opin Infect Dis. 2005 Oct;18(5):420-6
pubmed: 16148529
J Am Coll Nutr. 2000 Apr;19(2 Suppl):165S-175S
pubmed: 10759141
Int J Mol Sci. 2018 May 09;19(5):
pubmed: 29747442
Nat Biotechnol. 1997 Jul;15(7):653-7
pubmed: 9219268
Int J Food Microbiol. 2010 Nov 15;144(1):104-10
pubmed: 20884069
J Biotechnol. 2013 Oct 20;168(2):120-9
pubmed: 23664884
Clin Immunol. 2007 Apr;123(1):30-9
pubmed: 17218154
Hum Vaccin Immunother. 2014;10(6):1611-21
pubmed: 24732667
World J Gastroenterol. 2008 Apr 28;14(16):2511-6
pubmed: 18442197
World J Gastroenterol. 2004 Feb 1;10(3):455-7
pubmed: 14760780
Int J Mol Sci. 2016 Sep 14;17(9):
pubmed: 27649150
FEMS Microbiol Lett. 2004 Nov 15;240(2):131-6
pubmed: 15522499
J Exp Med. 1991 Dec 1;174(6):1549-55
pubmed: 1744584
J Microbiol Biotechnol. 2015 Apr;25(4):469-78
pubmed: 25348696
J Microbiol Methods. 2019 Apr;159:112-119
pubmed: 30529116
Blood. 1994 May 1;83(9):2678-83
pubmed: 8167346
Arch Microbiol. 2010 Sep;192(9):769-74
pubmed: 20631991
J Microbiol Biotechnol. 2007 Jul;17(7):1120-6
pubmed: 18051322
Nat Immunol. 2014 May;15(5):423-30
pubmed: 24681566
J Microbiol Biotechnol. 2012 Dec;22(12):1714-23
pubmed: 23221535
Science. 2000 Aug 25;289(5483):1352-5
pubmed: 10958782
Science. 2017 May 5;356(6337):513-519
pubmed: 28473584
Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G1025-34
pubmed: 18787064
Biochemistry. 1998 Dec 1;37(48):16943-51
pubmed: 9836587
Enzyme Microb Technol. 2000 Dec;27(10):761-765
pubmed: 11118583
Cold Spring Harb Perspect Biol. 2019 Feb 1;11(2):
pubmed: 29038121
Nat Immunol. 2007 Dec;8(12):1363-71
pubmed: 17994025
Gut. 2002 Feb;50(2):191-5
pubmed: 11788558
Microb Cell Fact. 2015 Sep 16;14:137
pubmed: 26377321
Br J Pharmacol. 1996 Sep;119(2):351-9
pubmed: 8886420
J Nutr. 2004 Jan;134(1):153-6
pubmed: 14704309
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31611251
Clin Rev Allergy Immunol. 2002 Jun;22(3):275-85
pubmed: 12043385
Annu Rev Immunol. 2001;19:683-765
pubmed: 11244051
J Immunol. 1991 Dec 1;147(11):3815-22
pubmed: 1940369
Microorganisms. 2020 May 25;8(5):
pubmed: 32466189
Curr Top Microbiol Immunol. 2014;380:19-38
pubmed: 25004812
J Microbiol Biotechnol. 2019 Nov 28;29(11):1717-1728
pubmed: 31581381
Methods Mol Biol. 2003;226:3-6
pubmed: 12958470
J Appl Microbiol. 2004;96(2):230-43
pubmed: 14723684
Front Microbiol. 2014 Aug 21;5:437
pubmed: 25191315
Clin Gastroenterol Hepatol. 2006 Jun;4(6):754-9
pubmed: 16716759
Front Microbiol. 2018 Dec 21;9:3075
pubmed: 30622516
Appl Environ Microbiol. 2008 Feb;74(3):660-6
pubmed: 18083875